(NASDAQ: TVTX) Travere Therapeutics's forecast annual revenue growth rate of 41.66% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.57%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.85%.
Travere Therapeutics's revenue in 2025 is $233,175,000.On average, 7 Wall Street analysts forecast TVTX's revenue for 2025 to be $31,664,588,412, with the lowest TVTX revenue forecast at $23,884,324,168, and the highest TVTX revenue forecast at $37,323,970,816. On average, 7 Wall Street analysts forecast TVTX's revenue for 2026 to be $46,406,935,706, with the lowest TVTX revenue forecast at $35,779,010,445, and the highest TVTX revenue forecast at $59,562,171,211.
In 2027, TVTX is forecast to generate $58,163,276,594 in revenue, with the lowest revenue forecast at $45,494,246,595 and the highest revenue forecast at $71,786,969,641.